Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting
Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.